financetom
Business
financetom
/
Business
/
UniCredit CEO says no plans to abandon Commerzbank investment, newspaper reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UniCredit CEO says no plans to abandon Commerzbank investment, newspaper reports
Jul 11, 2025 12:41 AM

MILAN (Reuters) -UniCredit has no plans to heed the advice of the German government to drop its ambitions to take over Commerzbank, the Italian bank's CEO was quoted as saying on Friday.

German Finance Minister Lars Klingbeil on Thursday told press agency DPA that the government expected UniCredit to abandon its takeover plans, reiterating that Berlin saw the approach as "unfriendly" and backed Commerzbank's independence.

"On Commerzbank we'll press ahead despite the German government's stance. We were invited in September to buy a 4.5% stake, it's not clear why we should go away now," Il Messaggero quoted UniCredit CEO Andrea Orcel as telling a board meeting on Thursday.

UniCredit this week doubled its equity and voting stake in Commerzbank by turning derivatives into shares.

It lifted the equity portion of its 29% stake in Commerzbank to around 20%, from 9% previously, and said it would eventually acquire the full position in equity.

"We'll convert the remaining derivatives and go to 29%. We have asked for a meeting to outline our strategy and we'll wait until we're listened to. Our approach is respectful of Commerzbank's specific characteristics," Orcel was quoted as saying.

UniCredit first emerged as the biggest private investor in Commerzbank in September when it bought 4.5% from the German government and disclosed a similar-sized stake it had built in the preceding months.

In December it used derivatives to increase the stake, and this year obtained European Central Bank approval to own up to 29.9% of Commerzbank. 

Orcel's acquisition strategy has run into difficulties at home, with a bid for smaller peer Banco BPM hampered by conditions the Italian government has set to authorise it.

A court ruling on UniCredit's appeal against the government's conditions is due by July 16. UniCredit has asked the court to annul the entire decision. It could modify only some of the terms.

"We would still be in an uncertain situation which discourages investors, weighs on the market, like I said before, the conditions to go ahead with the deal are not there," Il Messaggero quoted Orcel as saying. 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Parkland Corporation To Be Acquired By Sunoco LP
BRIEF-Parkland Corporation To Be Acquired By Sunoco LP
May 26, 2025
May 5 (Reuters) - Parkland Corp ( PKIUF ): * PARKLAND CORPORATION TO BE ACQUIRED BY SUNOCO LP * PARKLAND CORP ( PKIUF ) - AGREEMENT INCLUDES $275 MILLION BREAK FEE Source text: Further company coverage: ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Top Premarket Decliners
Top Premarket Decliners
May 26, 2025
07:57 AM EDT, 05/05/2025 (MT Newswires) -- DiamondRock Hospitality ( DRH ) shares were down 21% pre-bell Monday following a 3% increase in the previous session. Olema Pharmaceuticals ( OLMA ) stock was 19% lower, reversing from Friday's advance. Landsea Homes ( LSEA ) shares were down more than 18% after a 4% gain in the previous session. Unusual Machines...
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint
May 26, 2025
07:56 AM EDT, 05/05/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Monday that a phase 2 study of PTC518, or votoplam, in stage 2 and 3 Huntington's disease met its primary endpoint of reduction in blood Huntingtin protein levels at week 12. The company said the study showed dose-dependent lowering of blood Huntingtin levels, with 23% at the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved